MedTrace Logo

Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

NCT03808805 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-12-03

No results posted yet for this study

Summary

Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.

Conditions

  • Myeloproliferative Disorder
  • Aquagenic Pruritus

Interventions

DRUG

Aprepitant 80 mg

oral therapy - daily dose - 14 days

DRUG

Hydroxyzine 25mg

oral therapy - daily dose - 14 days

DRUG

Placebo of Hydroxyzine

oral therapy - daily dose - 14 days

DRUG

Placebo of Aprepitant

oral therapy - daily dose - 14 days

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Jean-Christophe IANOTTO, MD, PhD · Hématologie Clinique-Institut de Cancéro-Hématologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-16
Primary Completion
2023-09-01
Completion
2024-08-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03808805 on ClinicalTrials.gov